On June 15, 2012 Alan Minsk was quoted in the Law360 article “FDA Probe Could Grow To Encompass Fresenius Empire.” “The FDA could say, ‘Is this just a one-off, or this systematic of a larger issue?'” Mr. Minsk says in the article. He goes on to say that a warning letter from the FDA could encourage litigation. “A plaintiffs’ lawyer could go to a judge and jury and say, ‘I’ve got a letter from a government agency that says you violated the law. You knew there was a problem — how much do you want to start settling for?'” FDA investigated the decision by Fresenius Medical Care North America to alert company-affiliated physicians of cardiac risks linked to a dialysis treatment months before other health professionals.